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The number of elderly people is growing at an unprecedented rate and this increase
of the aging population is expected to have a direct impact on the incidence of
age-related diseases and healthcare-associated costs. Thus, it is imperative that new
tools are developed to fight and slow age-related diseases. Regenerative medicine
is a promising strategy for the maintenance of health and function late in life;
however, stem cell-based therapies face several challenges including rejection and
tumor transformation. As an alternative, the placenta offers an extraordinary source of
fetal stem cells, including the amniotic epithelial cells (AECs), which retain some of the
characteristics of embryonic stem cells, but show low immunogenicity, together with
immunomodulatory and anti-inflammatory activities. Because of these characteristics,
AECs have been widely utilized in regenerative medicine. This perspective highlights
different mechanisms triggered by transplanted AECs that could be potentially useful
for anti-aging therapies, which include: Graft and differentiation for tissue regeneration in
age-related settings, anti-inflammatory behavior to combat “inflammaging,” anti-tumor
activity, direct lifespan and healthspan extension properties, and possibly rejuvenation
in a manner reminiscent of heterochronic parabiosis. Here, we critically discuss benefits
and limitation of AECs-based therapies in age-related diseases.
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INTRODUCTION
Among the health challenges of this century, aging itself represents one of the main risk factor
for diseases (Niccoli and Partridge, 2012). In fact, aging is associated with a general decline in
the homeostasis and regeneration of the body, which often leads to common age-related diseases.
The mechanisms underlying age-related dysfunctions are heterogeneous and include a generalized
decrease in tissue regenerative responses (López-Otín et al., 2013). In the adult body, tissue-specific
stem cells are involved in the regeneration and repair of various tissues and organs, and, for a long
time, they were considered as a fountain of youth and a panacea to cure several diseases. Fetal stem
cells are gaining great interest in regenerative medicine, especially in the last decades, due to their
ease of collection and safety (Miki et al., 2005). A large amount of preclinical studies has confirmed
that fetal stem cells are the ideal candidates for transplantation and organ repair (Silini et al.,
2015) because they are non-tumorigenic after transplantation (Akle et al., 1981). Furthermore, the
immunomodulatory properties of amniotic membrane-derived stem cells allow their use in anti-
inflammatory therapies (Insausti et al., 2014). Transplantation of amniotic epithelial cells (AECs)
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has already been tested for different diseases in preclinical
settings; however, more recently, a few studies have also tested
their potential in fighting age-associated disorders in animal
models.
In this perspective, we will discuss all these aspects with a
particular focus on how aging research could potentially benefit
from the utilization of AECs.
STEM CELLS SOURCES
Stem cells are specialized cells of the body that are capable
of self-renewal and differentiation. For regenerative therapy,
various cell populations at different developmental stages have
been considered for transplantation, including embryonic stem
cells (ESCs), fetal and adult cells, and experimentally generated
induced pluripotent stem cells (iPSC). The zygote is perhaps
the most primitive “stem cell” and, right after fertilization, it
undergoes a series of rapid divisions that all appear to be
self-renewal divisions as every single cell of the blastomere is
undifferentiated. From this state, differentiation divisions begin
to occur as cells rearrange themselves at day 5 to form a cavity
(blastocoele) in which an inner cell mass is surrounded by
trophoectoderm cells (Moore and Persaud, 1998; Figure 1). It
is at this stage that ESCs are collected from the inner cell mass.
Because they retain pluripotency features (Thomson et al., 1998),
ESCs are considered the gold standard of stem cells: They are
widely used for basic research to study in vivo embryogenesis
and development and for regenerative medicine (Murry and
Keller, 2008), although with some limited success. In fact, ESCs
are highly pluripotent cells capable of forming teratomas after
transplantation and may be subject to rejection. The ethical
concerns regarding the collection of ESCs from embryos has led
researchers to overcome these limitations by using iPSCs, adult
cells reprogrammed to a pluripotency state by forced expression
of specific genes. In 2006, Yamanaka and colleagues were the
first to describe that the introduction of four genes encoding
the transcription factors Oct4 (octamer-binding protein 4, also
known as Pou5f1), Sox2 (SRY-related HMG-box gene 2), cMyc,
and Klf4 (Kruppel-like factor 4) could convert adult cells into
pluripotent stem cells (Takahashi and Yamanaka, 2006). This
represented a milestone in stem cell biology as it opened new
approaches to study and combat diseases. Unfortunately, forced
expression of cMyc and Klf4, which encode proto-oncogene
proteins, increases the rate of cancer transformation (Ben-David
and Benvenisty, 2011). More recently, studies have used other
genes and different techniques to improve the poor efficiency
of iPSC reprogramming; nevertheless, these cells still exhibit
tumorigenic properties in vivo and can elicit an immune response
(Zhao et al., 2011).
Adult tissue specific stem cells, like hematopoietic precursors,
muscle satellite cells, and bone marrow-derived mesenchymal
stem cells, are also limited in their potential for regenerative
medicine as their function is limited to only their specific tissue,
they can induce immune-rejection responses, and acquiring
adequate numbers of tissue-specific stem cells for regenerative
studies can often be challenging due to their rarity as well as
limited ex vivo maintenance and expansion techniques (Müller
et al., 2016).
A potential alternative to circumvent these limitations that
emerged in the last decades is the utilization of fetal-derived
stem cells. Amniotic stem cells can be collected from different
fetal annexes (amnion, chorion, amniotic fluid, Wharton jelly)
and have been proven to be safe, easy to collect, and devoid of
immunogenic and tumorigenic properties (Mamede et al., 2012;
Saito et al., 2012; Murphy and Atala, 2013; Pozzobon et al.,
2014). AECs are collected from the epithelial layer of the amnion
which derives directly from the epiblast as it retains some ESC
characteristics. In fact, after implantation, the inner cell mass
re-organizes and, driven by differential gene expression, divides
into a double layer of cells (Zernicka-Goetz et al., 2009), i.e.,
the hypoblast that migrates to the free surface of the inner cell
mass and gives rise to the endoderm; and the epiblast, which
will form the rest of the embryo (Zernicka-Goetz et al., 2009).
Before gastrulation, cells from the epiblast form a membrane,
the amnion, within which the human embryo and later the fetus
develops until birth (Moore and Persaud, 1998; Figure 1). AECs
express some of the ESCs surface markers, such as stage-specific
embryonic antigens (SSEA) 3 and 4, tumor rejection antigens
(TRA) 1-60 and 1-81, and molecular markers of pluripotency,
including Oct4, Sox2, and Nanog (Parolini et al., 2008). Their
plasticity was first confirmed in vitro by chimera formation
using mouse ESCs (Tamagawa et al., 2004) and later by the
production of cell types from all three germ layers using specific
cell differentiation protocols (Miki et al., 2005; Parolini et al.,
2008).
AECS TRANSPLANTATION TO IMPROVE
ORGAN FUNCTIONS
With old age, a generalized malfunction of stem cells may
be responsible for the emergence of various chronic diseases,
such as osteoporosis, type 2 diabetes mellitus, Parkinson’s
disease, atherosclerosis, and cancer, to name a few (Boyette
and Tuan, 2014). Although the integrity of aging tissues is
severely compromised by the altered number and function of
stem cells, the reactivation of specific populations of progenitor
cells through cell transplantation may represent a viable avenue
in anti-aging therapies (Figure 2). Since the beginning of the
twentieth century, amniotic cells have been shown to have
potential in regenerative medicine (Silini et al., 2015), with
transplanted AECs implementing the healing process either
through direct grafting of the tissue/organ to be repaired or by
the secretion of anti-inflammatory and anti-fibrotic molecules
(discussed below), although most of the times both mechanisms
act simultaneously.
More recently, several findings in preclinical research have
shown successful grafting and active proliferation of AECs
when transplanted in injured organs of various animal models,
which led to the establishment of a dozen clinical studies
(www.clinicaltrials.gov). The beneficial effects of amniotic
cell therapy have been shown also in several tissues that
are implicated in age-related diseases, including the nervous
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FIGURE 1 | Development of the amniotic sac during embryogenesis: After fertilization, the zygote undergoes a series of cell division and starts to
differentiate at the blastocyst stage in which only cells of the inner cell mass, and subsequently the epiblast, will give rise to the embryo. Amniotic
epithelial cells are collected from the amniotic sac that will form directly from the epiblast. (The path from the epiblast to the amniotic cells is depicted in magenta).
system/brain and liver as well as the cardiovascular and
musculoskeletal systems (Figure 2). For example, in rat models,
AECs can graft in the nerve fiber in the corpus callosum
in healthy animals (Wu et al., 2012) and participate in the
regeneration of transected optic nerve to facilitate the process
of neural restoration following injury (Xie et al., 2015a). The
therapeutic potential of AECs is further illustrated by their ability
to repair and/or improve brachial plexus injury (Yang et al.,
2014) and spinal cord injury (Meng et al., 2008), while improving
markers of Parkinson’s disease in rats (Yang et al., 2010).
Moreover, mechanical allodynia caused by microglia activity
in injured spinal cord is significantly suppressed with AECs
transplantation (Roh et al., 2013). Similarly, AECs can reduce
brain edema and motor deficit in intracerebral hemorrhagic rats
(Dong et al., 2010). The transplantation of humanAECsmitigates
many age-associated phenotypes in the Niemann-Pick type C1
mice including extension of life span, reduction in rapid weight
loss, and alleviation of tissue damage (Hong et al., 2012).
Grafting of AECs in the liver of immunocompromised SCID
mice promotes their differentiation into hepatocytes (Miki et al.,
2009; Marongiu et al., 2011) while injection of AECs around
the cardiovascular infarction area enables their differentiation
into cardiomyocyte-like cells with ensuing decrease in infarct
size and improved cardiac function in rats (Fang et al., 2012).
Other therapeutic applications of AECs in laboratory animals
include support of the regenerative process in tendon defects
(Barboni et al., 2012a,b) via collagen type I production (Muttini
et al., 2013), improvement in bone regeneration in vivo through
implantation of scaffold-loaded AECs (Barboni et al., 2013), and
reduction in the early host immune response to the scaffold
(Jiawen et al., 2014).
Despite these advances, there are some limitations including
the fact that the large majority of the studies were conducted
in young animal recipients and, therefore, the efficacy of AECs
transplantation in humans remains largely untested. This is
especially true for elderly patients due to the bigger risk of
graft failure (Hubbard and Dashti, 2011); indeed, challenges
in transplantation are greater in older adults than in younger
recipients, partly due to underlying pathologies, dysregulation
of the immune system, and uncertain long-term outcomes after
organ transplantation (Goldstein, 2012). Nevertheless, the results
in preclinical research appear promising in the treatment and
cure for age-related conditions and deserve further investigation.
COMBAT INFLAMMAGING
Persistent low grade inflammation accelerates the aging process
and is involved in multiple diseases. This process, termed
“inflammaging,” has been associated with tissue degeneration
and increased mortality and morbidity in the elderly (Franceschi
et al., 2000). Intrinsic and extrinsic factors contribute to
inflammaging, which include immunosenescence and/or
abnormal extrinsic activation of the immune system either by
environmental factors, defective somatic cells, or senescent
cells (Franceschi and Campisi, 2014). Senescence is a protective
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FIGURE 2 | Potential utilization of AECs in age-related diseases.
mechanism that cells mount in response to different stress
stimuli to avoid possible malignant transformation (Rodier and
Campisi, 2011). Senescent cells cease to proliferate, but they are
metabolically and transcriptionally active, capable of releasing
inflammatory mediators implicated in the senescence-associated
secretory phenotype (SASP) (Coppé et al., 2010). The secretion
of IL-6, IL1β, and TNFα during inflammaging is a consequence
of the activation of NF-κB and STAT transcription factors
(Bollrath and Greten, 2009), and is involved in the pathogenesis
of most age-associated diseases. In fact, the levels of these
cytokines are usually significantly higher in elderly patients
with cancer, cardiovascular diseases, rheumatoid arthritis,
diabetes, multiple sclerosis, and cognitive decline than in healthy
individuals (Prasad et al., 2012). It follows that the potential
anti-inflammatory properties of transplanted amniotic cells
could be used as a therapy to combat inflammaging.
The immune-privileged nature of placenta-derived AECs
allows maternal tolerance of the fetus. During pregnancy, the
mother’s body hosts a semi-allogenic fetus and has developed
subtle tolerance mechanisms to avoid rejection due to paternal
antigens and impairment in the general response to pathogens
(Hemberger, 2013). Subpopulations of leukocytes of the innate
and adaptive immune systems that reside in the placenta increase
during pregnancy (Hemberger, 2013), consistent with a transient,
antigen-specific immune suppression. The low levels of both
MHC class I surface antigens and the major components of
the antigen-processing machinery represent a highly conserved
feature of AECs among various animal species (Banas et al.,
2008) despite differences in embryogenesis and formation of the
annexes. AECs constitutively express the non-classical human
leukocyte antigen G (HLA-G) (Insausti et al., 2014), this is
tissue-restricted and is usually found in immune-privileged
organs like eye, testis and brain, where it exerts tolerogenic
properties by modulating the activities of both T and B
lymphocytes, NK cells, and dendritic cells (Rouas-Freiss et al.,
1999).
Due to these unique characteristics, AECs are a valuable tool
for fighting inflammaging. The mechanisms implicated in the
immunosuppressive and immunomodulatory properties of AECs
have been elucidated using various target cells of the innate
and the adaptive immune systems. AECs inhibit alloreactive
T-lymphocytes in a mixed lymphocyte reaction (Pianta et al.,
2015) and they also foster the switch from T-helper (Th) 1
and Th17 lymphocytes, to Th2 and Treg (Pianta et al., 2015),
and M1 to M2 macrophages (Manuelpillai et al., 2012) through
the release of anti-inflammatory cytokines. AECs also block
maturation of monocytes into dendritic cells (Magatti et al.,
2009) and inhibit proliferation of activated peripheral blood
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mononuclear cells in vitro (Wolbank et al., 2007) partly through
the secretion of anti-inflammatory cytokines (Kang J. W. et al.,
2012).
AECs reduce pulmonary fibrosis and inflammation (Moodley
et al., 2010) through Treg cell regulation (Tan et al., 2015).
AECs have been found to also lower the number of pulmonary
leucocytes and expression of pro-inflammatory markers (e.g.,
TGF-β, PDGF-α, PDGF-β, TNF-α, IFN-γ, and IL-6) that resulted
in the normalization of lung tissue density, collagen content,
and production of smooth muscle actin (α-SMA) (Murphy et al.,
2011; Vosdoganes et al., 2013a). Moreover, AECs promote a pro-
reparative M2 phenotype by directly modulating macrophage
behavior (Tan et al., 2014). When administered to neonatal
mice, AECs partially reduce hyperoxia-induced inflammation
and structural damage of the lung (Vosdoganes et al., 2013b)
while attenuating the fetal pulmonary inflammatory response to
experimental intrauterine inflammation in sheep (Vosdoganes
et al., 2011).
AEC transplantation also results in an effective treatment for
liver inflammation and fibrosis. Sustained hepatic inflammation
is a key prerequisite for fibrogenesis and is characterized by an
activation of fibrogenic hepatic stellate cells and macrophages,
both of which being reverted by the treatment with AECs
(Manuelpillai et al., 2012; Hodge et al., 2014). The anti-fibrotic
activity of transplanted AECs is accompanied by a reduction
in hepatic TNF-α, IL-6, and TGF-β levels, and an induction
in IL-10 levels and metalloproteinase-2 activity (Manuelpillai
et al., 2010). Studies on the nervous system have also reported
that AECs inhibit microglia activation, reduce brain edema,
and improve neurological deficit in a rat model of intracerebral
hemorrhage through downregulation of TNF-α, Il-1β, andMMP-
12 (Liang et al., 2014). The transplantation of AECs may even be
beneficial against multiple sclerosis (Liu et al., 2012, 2014) and in
immunosuppressant therapy with implication in pancreatic islet
transplantation (Qureshi et al., 2011).
ANTI-TUMOR EFFECTS OF AECS
Carcinogenesis is one of the leading causes of death in the
older population. The utilization of stem cell transplantation
is now being considered an anticancer therapy along with
surgery, chemotherapy, and radiotherapy. Non-engineered and
engineered stem cells have a number of features that make them
useful as gene delivery vehicles in anticancer protocols (Kang
et al., 2012a). In a breast cancer model, AECs reduce tumor
progression and tumor size without compromising the normal
breast tissue (Kang et al., 2012b). There is evidence that AECs
inhibit tumor growth through the release of soluble molecules
responsible for cell cycle blockade and/or apoptosis induction.
Injection of AECs into growing tumors reduces their final size
through increased activation of a proapoptotic signaling response
(e.g., caspase 3 and 8 activity) and reduction in Bcl-2 protein
levels (Niknejad et al., 2014). Finally, AEC transplantation blocks
tumor proliferation in the G0/G1 phase by inhibiting cyclins (D2,
E1, and H) and cyclin-dependent kinases without induction of
apoptosis (Magatti et al., 2012; Di Germanio et al., 2016).
The notion that AECs possess anti-angiogenic properties
that would inhibit or at least decrease nutrient and oxygen
availability to combat metastasis spread of malignant tumors
is rather controversial (Zhu et al., 2016). It is likely that the
conflicting conclusions reached on the anti- vs. pro-angiogenic
properties of AECs depend on the different tissues and/or
experimental outcomes measured, ranging from tumor growth
to epithelialization.
DIRECT ANTI-AGING AND REJUVENATING
EFFECTS
The utilization of AECs in regenerative medicine already covers
a vast array of diseases and can ultimately be of use in anti-
aging therapies. The transplantation of amniotic cells in a mouse
model of premature aging delays senescence in the recipient
animals following grafting and differentiation into multiple
tissues and organs (Xie et al., 2015b). Lymphocyte dysmaturity
and osteoporosis are also ameliorated after transplantation of
amniotic cells into Bmi-1−/− mice, with a subsequent decrease
in oxidative stress and DNA damage (Xie et al., 2015b). Once-a-
month transplantation of amniotic cells slows cognitive decline
and improves the physical function of aging rats, leading to
an increase in lifespan (Kim et al., 2015). Similarly, it was
previously shown that transplantation of young mesenchymal
stromal cells significantly slows the loss of bone density and
prolongs the lifespan of old mice (Shen et al., 2011). We recently
reported that the blockade of SASP by AEC-derived conditioned
medium delays the onset of senescence in cultured fibroblasts
(Di Germanio et al., 2016), consistent with the idea that extrinsic
environmental factors can influence cell behavior. Vital organs,
tissues, and the in vivomilieu slowly loose some function during
aging. The technique of heterochronic parabiosis, where two
animals of different ages are joined together surgically to create
shared circulatory system, illustrates that factors in young blood
can rejuvenate aged stem cells from muscle, liver and brain
in mice (Conboy et al., 2005). The administration of young
blood improves also cognitive function and rejuvenates synaptic
plasticity in old mice (Villeda et al., 2014), supporting the notion
that cellular aging not only depends on intrinsic factors, such as
DNA damage and ROS accumulation, but also relies on extrinsic
factors (Conboy et al., 2015). To date, GDF11 (although very
controversial) (Loffredo et al., 2013), oxytocin (Elabd et al., 2014),
klotho (Kuro-o et al., 1997) have been described as “rejuvenation”
circulating factors and it remains to be seen whether they can
provide a youthful phenotype in the entire aged animal.
Pregnancy represents the only naturally occurring
heterochronic parabiosis system, where fetal and maternal
entities coexist and share the same circulation. A small number
of fetal cells appears in the circulatory system and organs of the
mother, starting at 6 weeks of pregnancy (Bianchi, 2012; Nelson,
2012), and this fetal microchimerism can somehow rejuvenate
the mother (Falick Michaeli et al., 2015a). Recruitment of
fetal progenitor cells to maternal wounds has been found to
participate in the inflammatory and angiogenic responses
(Nassar et al., 2012a,b; Mahmood and O’Donoghue, 2014). In
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addition, pregnancy offers beneficial effect on liver and muscle
regeneration even though no fetal cells have been found at the
site of injury (Gielchinsky et al., 2010; Falick Michaeli et al.,
2015b). However, microchimerism can also elicit detrimental
effects, especially in auto-immune diseases (Nelson, 2012). The
origin of the cells involved in microchimerism is unknown,
but amniotic cells have been proposed to be implicated in this
phenomenon (Rosner and Hengstschläger, 2013). From this
body of data, one could speculate that the presence of very
young amniotic cells in the mother’s circulation exerts similar
effects and, therefore, can explain the beneficial and rejuvenating
properties of amniotic cell transplantation.
CONCLUSIONS AND CURRENT
LIMITATIONS
Regenerative medicine strategies to combat age-associated
phenotypes will benefit substantially from improved
understanding of the intricate biology of stem cells. Following
transplantation, exogenous stem cells can graft and replace
dysfunctional tissues or improve the tissue milieu, possibly
through anti-inflammatory and anti-fibrotic mechanisms.
Moreover, the AEC secretome contains an array of molecules
and proteins capable of replicating most of the properties of
AECs (Di Germanio et al., 2016). Although these strategies may
ultimately help alleviate some age-related diseases, there are some
important caveats that limit the translation of animal studies
into clinical trials. For example, although these cells can be
expanded and maintained ex vivo, the yield and recovery of the
number of AECs can be quite variable and their characteristics
appear to be dependent on the genotype and age of the donor
and the collection method. Furthermore, the large majority of
existing studies on transplantation have been conducted on
young rather than old animals and, therefore, these findings need
to be independently confirmed.
In conclusion, there is still a long road ahead before stem cell-
based therapies can be used in clinical settings; however, existing
animal studies are encouraging and offer the opportunity for the
development and implementation of exploratory clinical trials
aimed at providing promising new therapeutic avenues in the
fight against age-related diseases.
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